Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE
A Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with SignateraTM MRD-Guided CDK4/6 Inhibitor Therapy in ER-Positive/HER2-Negative Early-Stage Breast Cancer Trial will utilize Natera’s ultrasensitive MRD test, Signatera Genome with Phased and Structural Variants, paired with giredestrant monotherapy, Genentech’s oral SERD, with the objective to spare patients from unnecessary CDK4/6…